non-small cell lung cancer
Conditions
Interventions
single arm:Concomitant thoracic radiotherapy with oral anlotinib
Sponsors
Shaoxing People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-85 years; 2. ECOG PS score: 0-2 points; 3. Life expectancy >= 12 weeks; 4. Confirmed by histopathology and/or cytology combined with imaging tests Patients with stage III-IV lung squamous cell carcinoma who are inoperable and cannot tolerate chemotherapy; 5. Have at least one measurable target lesion for further evaluation according to RECIST criteria; 6. Have a full understanding of this study, volunteer to participate, have follow-up conditions and sign informed consent; 7. The main organ functions are normal and should meet the following criteria: (1) Blood routine examination criteria (no blood transfusion within 14 days, no correction with G-CSF and other hematopoietic stimulating factors): hemoglobin (HB) >= 90 g/L, absolute neutrophils (ANC) >= 1.5x10^9/L, platelets (PLT) >= 80x10^9/L; (2) Biochemical tests should meet the following criteria: total bilirubin (TBIL) = 60 mL/min.
Exclusion criteria
Exclusion criteria: 1. Gene detection of tumor tissue or blood indicates that TPS or CPS expression is >= 50% in stage IV patients; 2. The tumor invades the deep layers of large blood vessels, and it is expected that there is a high probability of major bleeding in combination with thoracic radiotherapy and anlotinib; 3. Active bleeding, ulcers, intestinal perforation, intestinal obstruction, etc.; 4. Pregnant, breastfeeding women, or female patients who are fertile but not taking contraceptive measures; 5. Existing severe uncontrolled acute infection, or purulent and chronic infection, and persistent wound healing; 6. Patients with uncontrollable hypertension and grade 3-4 cardiac insufficiency; patients with uncontrollable mental, neurological diseases or mental disorders, poor compliance, unable to cooperate with filling out the quality of life scale; 7. Patients with obvious intracranial hypertension or neuropsychiatric disorders symptoms; 8. Concomitant with other malignant tumors and need active treatment; 9. Other conditions that the investigator considers unsuitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Disease control rate;Adverse reactions; | — |
Countries
China
Contacts
Public ContactWu Dongping
Department of Radiation Oncology, Shaoxing People's Hospital
Outcome results
None listed